Therapy for advanced gallbladder cancer: Improving survival

• DOI: 10.1200/jco.2008.26.15_suppl.15566
• Publication Date: 2017-02-24T07:33:44Z
• Authors: J. Gallardo; B. Rubio; M. Ahumada; O. Barajas; L. Villanueva; J. Diaz; X. De Aretxabala; J. Reyes
• Keywords: Gallbladder Cancer; Regimen; Biliary Tract Cancer

15566 Background: Gemcitabine (G) monotherapy and G + cisplatin (C) have showed significant response rate (RR), including some complete responses (CR), to increase survival time in patients (pts) with advanced gallbladder cancer (AGC), but results depend on the regimen that was used, for how long therapy given. Here we compare of four different modalities. Methods: We updated terms overall survival, safety cohorts patients, treated or GC regimens, two them formal phase II studies, others similar protocol, out study. All pts in/exclusion criteria studies being treated. Results: See table. Conclusions: Even thought there an improvement RR when v/s alone (cohort 2 cohort 1), median similar. When limitation 6 cycles maximum eliminated, 3), advantage combination impacted almost fold, this better could be also explained by second line chemotherapy. In last observe impact surgical resection highly selected pts. Note: Study conducted Grupo Oncológico Cooperativo Chileno Investigación GOCCHI. Cohort 1 3 4 N 26 44 32 8 Treatment 1,000 mg/m2 weekly ×3 every 28 days 1,200 C 40 8, Every 21 G1,000 ± Surgical Resection Infusion 30 min 60 100 Duration Chemotherapy Until disease progression and/or unacceptable toxicity toxicity. Maximal Second given Progression RC/PR/RR (%) 0/34.6/34.6 9/36.4/45.4 3.1/37.5/40.6 n/a Survival rates 33,8 w (4–152) 39 (1–260) 56,18 (2 162) 95.5 (32 Estimated 29 51 97 Pts alive 0 died due treatment No financial relationships disclose.